Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO Open

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera’s technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications.

Results from the phase III VOLGA trial in muscle-invasive bladder cancer (MIBC) were presented in a Presidential Symposium and highlighted Natera’s new Signatera Genome Assay with Phased and Structural variants.VOLGA evaluated a novel perioperative immunotherapy regimen and included an analysis of ctDNA dynamics before radical cystectomy. The results showed that Signatera ctDNA dynamics were highly predictive of event-free survival (EFS). Patients who were persistently Signatera-negative had a 24-month EFS rate of 91%, compared with 81% for those who started Signatera positive but cleared their ctDNA before surgery, and 55% for those who started positive and remained positive.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.